Subcutaneous administration of polymerized type I collagen downregulates interleukin (IL)-17A, IL-22 and transforming growth factor-β1 expression, and increases Foxp3-expressing cells in localized scleroderma

Clin Exp Dermatol. 2012 Aug;37(6):599-609. doi: 10.1111/j.1365-2230.2012.04385.x. Epub 2012 Jun 25.

Abstract

Background: Localized scleroderma (LS) is a disfiguring inflammatory autoimmune disease of the skin and underlying tissue. As in systemic sclerosis, a key feature is the presence of T cells in inflammatory lesions.

Aim: To evaluate the effect of polymerized type I collagen vs. methylprednisolone (MP) in LS, and to determine the influence of this polymerized collagen (PC) on CD4+ peripheral T cells expressing interleukin (IL)-4, IL-17A, interferon-γ and Forkhead box protein (Foxp)3, and on cells expressing transforming growth factor (TGF)-β1, IL-17A, IL-22 and Foxp3 in the skin.

Methods: In total, 16 patients with LS were treated for 3 months with monthly subcutaneous intralesional injections of 0.1 mL MP (giving a total dose of 20 mg/mL each month) and 15 patients were treated, with weekly subcutaneous intralesional injections of PC, ranging from 0.2 mL (equivalent to 1.66 mg collagen) for a lesion of 50 mm in size, up to a maximum of 1.0 mL (8.3 mg collagen) for a lesion > 100 mm in size, and followed up for a further 6 months. Skin biopsies were obtained from lesions at baseline (before treatment) and 9 months later (6 months after treatment end). Tissue sections were evaluated by histology and immunohistochemistry (IL-17A, IL-22, TGF-β1 and Foxp3). CD4+ T-cell subsets were determined in peripheral blood by flow cytometry.

Results: Abnormal tissue architecture was seen in the biopsies taken from patients treated with MP, whereas the PC treatment restored normal skin architecture. PC downregulated pro-inflammatory/profibrotic cytokine expression in peripheral cells, and upregulated the number of regulatory T cells (Tregs) in skin. PC was safe and well tolerated.

Conclusions: PC is not only an antifibrotic/fibrolytic agent but also an immunomodulator biodrug that restores the balance between T helper (Th)1, Th2, Th17 and Tregs, downregulates production of pro-inflammatory or profibrogenic cytokines (IL-17A, IL-22 and TGF-β1), and renews skin architecture, without adverse effects.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Collagen Type II / administration & dosage*
  • Collagen Type II / pharmacology
  • Double-Blind Method
  • Down-Regulation
  • Female
  • Flow Cytometry
  • Forkhead Transcription Factors / metabolism*
  • Humans
  • Immunohistochemistry
  • Injections, Subcutaneous
  • Interleukin-17 / metabolism*
  • Interleukin-22
  • Interleukins / metabolism*
  • Male
  • Middle Aged
  • Prospective Studies
  • Scleroderma, Localized / drug therapy*
  • Scleroderma, Localized / metabolism
  • Scleroderma, Localized / pathology
  • T-Lymphocytes / metabolism
  • Transforming Growth Factor beta1 / metabolism*
  • Young Adult

Substances

  • Collagen Type II
  • FOXP3 protein, human
  • Forkhead Transcription Factors
  • Interleukin-17
  • Interleukins
  • Transforming Growth Factor beta1